The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1636
ISSUE1636
November 1, 2021
Empagliflozin (Jardiance) for Heart Failure with Reduced Ejection Fraction
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Empagliflozin (Jardiance) for Heart Failure with Reduced Ejection Fraction
November 1, 2021 (Issue: 1636)
The sodium-glucose cotransporter 2 (SGLT2) inhibitor
empagliflozin (Jardiance – Boehringer Ingelheim)
has been approved by the FDA for a third indication: to
reduce the risk of hospitalization for heart failure (HF)
and cardiovascular death in...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.